

57. (previously presented) Medical product obtainable in accordance with the method according to claim 51.
58. (previously presented) Medical product according to claim 1, characterized in that in the case of the medical product a stent is concerned.
59. (previously presented) Medical product according to claim 58, wherein the stent is suitable to prevent or to reduce restenosis.
60. (previously presented) Medical product according to claim 58, wherein the stent is suitable to continuously release at least one antiproliferative, antiinflammatory, antiangiogenic and/or antithrombotic active agent.

Claims 61-64. (canceled)

65. (previously presented) Medical product according to one of the claim 56, characterized in that in the case of the medical product a stent is concerned.
66. (previously presented) Medical product according to claim 65, wherein the stent is suitable to prevent or to reduce restenosis.
67. (previously presented) Medical product according to claim 65, wherein the stent is suitable to continuously release at least one antiproliferative, antiinflammatory, antiangiogenic and/or antithrombotic active agent.
68. (previously presented) Medical product according to one of the claim 57, characterized in that in the case of the medical product a stent is concerned.
69. (previously presented) Medical product according to claim 68, wherein the stent is suitable to prevent or to reduce restenosis.

methylosorbifolin, sphatheliachromen, stizophyllin, mansonine, strebloside, akagerine, dihydrousambarensine, hydroxyusambarine, strychnopentamine, strychnophylline, usambarine, usambarensine, berberine, liriodenine, oxoushinsunine, daphnoretin, lariciresinol, methoxylariciresinol, syringaresinol, umbelliferon, afromoson, acetylvismione B, desacetylvismione A, vismione A and B and sulfur containing amino acids such as cystine as well as salts and/or mixtures of the aforementioned active agents.

46. (previously presented) Medical product according to claim 45, characterized in that the active agent is chosen from the group comprising tacrolimus, pimecrolimus, PI-88, paclitaxel and its derivatives, trapidil, α - and β -estradiol, sodium salt of 2-methylthiazolidine-2,4-dicarboxylic acid, macrocyclic carbon suboxide (MCS) and its derivatives, sirolimus, fumaric acid and its esters, activated protein C, interleukin-1B inhibitors and melanocyte-stimulating hormone (α -MSH), cystine, ellipticine, bohemine, indanocine, colcemid and derivatives thereof, methionine as well as salts and/or mixtures of the aforementioned active agents.
47. (previously presented) Medical product according to claim 45, wherein at least one antiproliferative, antiinflammatory and/or antithrombotic active agent is bound covalently and/or adhesively under and/or in and/or on the polymer layer.
48. (previously presented) Medical product according to claims 45, characterized in that the antiproliferative, antiinflammatory and/or antithrombotic active agent according to claim 14 is contained in a pharmaceutically active concentration of 0.001 to 10 mg per cm² surface of the medical product.
49. (previously presented) Medical product according to claims 32, wherein the substances for the polymer layer contain a polymerization catalyst in a biocompatible concentration.

Claims 50-50. (canceled)

56. (previously presented) Medical product obtainable in accordance with the method according to claim 50.

enalapril, losartan, thio-protease inhibitors, prostacyclin, vapiprost, α , β and γ interferon, histamine antagonists, serotonin blockers, apoptosis inhibitors, apoptosis regulators such as p65, NF-kB or Bcl-xL antisense oligonucleotides, halofuginone, nifedipine, tocopherol, vitamin B1, B2, B6 and B12, folic acid, tranilast, molsidomine, tea polyphenols, epicatechin gallate, epigallocatechin gallate, Boswellinic acids and derivatives thereof, leflunomide, anakinra, etanercept, sulfasalazine, etoposide, dicloxacillin, tetracycline, triamcinolone, mutamycin, procainamid, D24851, SC-58125, retinoic acid, quinidine, disopyramide, flecainide, propafenone, sotalol, amidorone, natural and synthetically produced steroids such as bryophyllin A, inotodiol, maquiroside A, ghalakinoside, mansonine, streblolide, hydrocortisone, betamethasone, dexamethasone, non-steroidal substances (NSAIDS) such as fenoprofen, ibuprofen, indomethacin, naproxen, phenylbutazone and other antiviral agents such as acyclovir, ganciclovir and zidovudine, antimycotics such as clotrimazole, flucytosine, griseofulvin, ketoconazole, miconazole, nystatin, terbinafine, antiprozoal agents such as chloroquine, mefloquine, quinine, moreover natural terpenoids such as hippocaesculin, barringtogenol-C21-angelate, 14-dehydroagrostistachin, agroskerin, agrostistachin, 17-hydroxyagrostistachin, ovatodiolids, 4,7-oxycycloanisomelic acid, baccharinoids B1, B2, B3 and B7, tubeimoside, bruceanol A, B and C, bruceantinoside C, yadanziosides N and P, isodeoxyelephantopin, tomenphantopin A and B, coronarin A, B, C and D, ursolic acid, hyptatic acid A, zeorin, iso-iridogermanal, maytenfoliol, effusantin A, excisanin A and B, longikaurin B, sculponeatin C, kamebaunin, leukamenin A and B, 13,18-dehydro-6- α -seneciolyloxychaparrin, taxamairin A and B, regenilol, triptolide, moreover cymarin, apocymarin, aristolochic acid, anopterin, hydroxyanopterin, anemonin, protoanemonin, berberine, cheliburin chloride, cictoxin, sinococuline, bombrestatin A and B, cudraisoiflavone A, curcumin, dihydronitidine, nitidine chloride, 12- β -hydroxypregnadiene-3,20-dione, bilobol, ginkgol, ginkgolic acid, helenalin, indicine, indicine-N-oxide, lasiocarpine, inotodiol, glycoside 1a, podophyllotoxin, justicidin A and B, larreatin, malloterin, mallotochromanol, isobutyrylmallotochromanol, maquiroside A, marchantin A, maytansine, lycoridicin, margetine, pancratistatin, liriodenine, oxoushinsunine, aristolactam-AII, bisparthenolidine, periplocoside A, ghalakinoside, ursolic acid, deoxypsorospermin, psychorubin, ricin A, sanguinarine, manwu wheat acid,